SEP 16, 2020 10:00 AM PDT

New Crossroad: The Intersection of COVID-19 and Sepsis

Sponsored by: BD
C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Division Director for "Molecular and Microbial Diagnostics and Development", Department of Laboratory Medicine, Geisinger
    Biography
      Dr. Wolk serves as the Division Director for “Molecular and Microbial Diagnostics and Development” in the Department of Laboratory Medicine at Geisinger, an integrated healthcare delivery network serving ~ 3 million people in Central PA.                                                                            A Diplomate of the American Board of Medical Microbiology (ABMM), Dr. Wolk’s professional practice extends to the national and international level. She serves on CLIAC, providing scientific and technical guidance to the US Dept. of Health and Human Services, and serves as a liaison to the CDC’s Board of Scientific Counselors for the Office of Infectious Diseases. She is the Diagnostic Microbiology Lead for Project Santa Fe’s Clinical Laboratory 2.0 initiatives and was recently elected as incoming chair of the Infectious Disease subdivision for the Association of Molecular Pathology. Dr. Wolk is the lead investigator for Geisinger’s Center for Laboratory Innovations and Outcomes, and chair of the Diagnostic Medicine Institute's Clinical Research Council. Her translational research efforts focus on evaluation and evidence-based integration of new technology for infectious disease diagnostics, and she leads the ASM/Center for Disease Control’s Laboratory Medicine Best Practice initiatives to characterize the rapid diagnosis of bacteremia, and is a Professor at Geisinger Commonwealth School of Medicine. In 2012, she was awarded the 1885 Society’s Distinguished Scholar’s Award at the University of Arizona; in 2016 she received the American Society for Microbiology’s BD Award for Clinical Research in Microbiology; in 2018, her career was highlighted in the ASM Press book entitled “Women in Microbiology.” Dr. Wolk’s post-doctoral fellowship was in Medical and Public Health Microbiology at Mayo Clinic, her Ph.D. was awarded in Pathobiology at the University of Arizona, and she earned a Master’s in Health Administration from Wilkes University, with a B.S. in Microbiology/ Medical Technology from Penn State University.

    Abstract
    Date:  September 16, 2020
    Time: 10:00am (PDT),  1:00pm (EDT)
     
    Individuals infected with COVID-19 can experience mild symptoms and recover while others can experience more serious illness and may require hospital care.
     
    COVID-19 clinical symptoms range from mild acute respiratory infection (ARI), severe acute respiratory infection (SARI) with progressive organ failure, sepsis and acute respiratory distress syndrome (ARDS).1 It has become clear that sepsis is a common complication in COVID-19 patients and an important risk factor for increased mortality. In a recent multicenter study, the risk factors associated with in-hospital deaths of 191 patients were analyzed and sepsis was the most frequently observed complication (100% of the non-survivors), followed by respiratory failure (98%), ARDS (93%), septic shock (70%) and heart failure (52%).2 Researchers are still investigating the pathogenic origin of sepsis in COVID-19 patients to understand whether it is directly caused by SARS-CoV-2 virus and/or a secondary source (bacterial, viral or fungal).
     
    Learning Objectives
    • Compare and contrast viral sepsis with focus on sepsis symptoms caused by SARS-CoV-2
    • The role of rapid testing for COVID-19 to support blood culture stewardship
     
     
    Webinars will be available for unlimited on-demand viewing after live event.
     
    LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.

    Show Resources
    You May Also Like
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    JUN 09, 2020 10:00 AM PDT
    C.E. CREDITS
    JUN 09, 2020 10:00 AM PDT
    DATE: June 9, 2020 TIME: 10:00am PT, 1:00pm ET The presentation will first discuss sepsis as a disease and then explain the importance of performing diagnostic tests in the clinical labora...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    JUL 22, 2020 10:00 AM PDT
    C.E. CREDITS
    JUL 22, 2020 10:00 AM PDT
    DATE: July 23, 2020 TIME: 10:00 am PDT The SARS-CoV-2 pandemic has taken a toll on many sectors of the medical community. As the pandemic took a grip on the laboratory, the need for diagnost...
    JUN 23, 2020 10:00 AM PDT
    C.E. CREDITS
    JUN 23, 2020 10:00 AM PDT
    DATE: June 23, 2020 TIME: 10:00am PT Human mesenchymal stromal or stem cells (MSCs)-based immunomodulation treatment has been proposed as a suitable therapeutic approach for many diseases, s...
    NOV 10, 2020 7:00 AM PST
    C.E. CREDITS
    NOV 10, 2020 7:00 AM PST
    DATE: November 10, 2020 TIME: 7:00am PDT, 10:00am EDT Automation can provide tremendous benefits such as increased pipetting precision and accuracy, productivity, and throughput. Numerous wo...
    Loading Comments...
    Show Resources
    Attendees
    • See more